Intranasal administration of convalescent plasma protects against SARS-CoV-2 infection in hamsters.

ABSTRACT:

Background

Convalescent plasma (CP) transfusion is an early option for treating infections with pandemic potential, often preceding vaccine or antiviral drug rollout. Heterogenous findings from randomized clinical trials on transfusion of COVID-19 CP (CCP) have been reported. However, meta-analysis suggests that transfusion of high titer CCP is associated with a mortality benefit for COVID-19 outpatients or inpatients treated within 5 days after symptom onset, indicating the importance of early administration.

Methods

We tested if CCP is an effective prophylactic against SARS-CoV-2 infection by the intranasal administration of 25 μL CCP/nostril (i.e. 0.01-0.06 mg anti-RBD antibodies/kg) in hamsters exposed to infected littermates.

Findings

In this model, 40% of CCP tr

SUBMITTER: Wouters E 

PROVIDER: S-EPMC10171892 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature